1996
DOI: 10.2165/00019053-199610050-00009
|View full text |Cite
|
Sign up to set email alerts
|

German Health Economic Cost Evaluation on Oral Ganciclovir in Treating Cytomegalovirus Retinitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
2
0
2

Year Published

1997
1997
2004
2004

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 11 publications
(4 citation statements)
references
References 7 publications
0
2
0
2
Order By: Relevance
“…For instance, this is the case for a study on growth factors (see 20 in Table 6, Mapelli et al, 1994), HIV (see 8 in Table 6; Schulenburg et al, 1996b) or on cystic fibrosis (see 11 in Table 6) which is a chronic pulmonary disease leading to frequent coughing and infections in the airways (Menzin et al, forthcoming).…”
Section: Methods Of Economic Evaluation Studies In Medical Carementioning
confidence: 99%
“…For instance, this is the case for a study on growth factors (see 20 in Table 6, Mapelli et al, 1994), HIV (see 8 in Table 6; Schulenburg et al, 1996b) or on cystic fibrosis (see 11 in Table 6) which is a chronic pulmonary disease leading to frequent coughing and infections in the airways (Menzin et al, forthcoming).…”
Section: Methods Of Economic Evaluation Studies In Medical Carementioning
confidence: 99%
“…Gesundheitsökonomische Evaluation kann allein deskriptiv sein, wie im Falle einer Kostenanalyse [66] oder unter Einbeziehung wirtschaftstheoretischer Modelle auch Hypothesen überprüfen und zielgerichtet eingesetzt werden (⊡ TabelAbb. 2 ▲ Erlöse für stationäre Behandlung mit differenten Erlösmodellen.…”
Section: Conditio Sine Qua Non: Offenlegung Der Perspektiveunclassified
“…Gerade die Behandlung oder Prophylaxe opportunistischer Infektionen ist ein weiterer kostenintensiver Bereich. Neben der medizinischen Indikation und Notwendigkeit ist auch die Wirtschaftlichkeit dieser Prophylaxen durch Studien belegbar [47,66].Auch zum Einsatz von Arzneien in diesem Indikationsgebiet bestehen Konsensusrichtlinien,die regelmäßig aktualisiert werden [63]. Das Vorgehen nach den Prinzipien der evidenzbasierten Medizin rechtfertigt dabei hinreichend den entstehenden Verzehr von ökonomischen Ressourcen.…”
Section: üBrige Pharmakaunclassified
“…Also, the supporting drugs deployment can vary in its standards: in some countries extremely potent drugs are deployed very early on in the course of an illness, partly even preventative, whereas in other countries which have a markedly different treatment pattern, particular drugs are only used when a particular complication arises (e.g., prevention against cytomegalovirus in transplants) [17]. The complication rate, for example, could be comparatively higher in a country where the regulations on sterility are less strict than in another country.…”
Section: Comparability Of Resource Consumptionmentioning
confidence: 99%